JPMorgan Chase & Co. Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $167.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective raised by JPMorgan Chase & Co. from $165.00 to $167.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

ASND has been the topic of a number of other research reports. Cantor Fitzgerald reaffirmed an overweight rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a report on Monday. Wells Fargo & Company increased their price objective on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an overweight rating in a research report on Friday, March 15th. Wedbush lifted their price objective on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an outperform rating in a research note on Thursday, February 8th. StockNews.com upgraded Ascendis Pharma A/S from a sell rating to a hold rating in a research note on Monday, December 25th. Finally, Jefferies Financial Group started coverage on Ascendis Pharma A/S in a report on Wednesday, December 20th. They issued a buy rating and a $150.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of Moderate Buy and an average target price of $173.25.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $147.65 on Tuesday. Ascendis Pharma A/S has a fifty-two week low of $66.03 and a fifty-two week high of $161.00. The stock has a market cap of $8.60 billion, a PE ratio of -15.96 and a beta of 0.50. The stock has a fifty day moving average of $147.16 and a 200-day moving average of $120.30.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, topping the consensus estimate of ($2.15) by $0.49. The business had revenue of $148.62 million during the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.16 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. raised its holdings in shares of Ascendis Pharma A/S by 1.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company’s stock valued at $2,064,000 after buying an additional 159 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Ascendis Pharma A/S by 3.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 422,854 shares of the biotechnology company’s stock worth $53,258,000 after acquiring an additional 12,881 shares in the last quarter. Perceptive Advisors LLC bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth approximately $16,648,000. FIL Ltd purchased a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at $755,000. Finally, Voloridge Investment Management LLC boosted its stake in shares of Ascendis Pharma A/S by 268.4% in the 4th quarter. Voloridge Investment Management LLC now owns 73,335 shares of the biotechnology company’s stock valued at $9,237,000 after purchasing an additional 53,427 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.